Background Multiple sclerosis (MS) is the most common neuroimmunological disease in young adults. Data on its clinical onset before the age of 18 (paediatric-onset MS (POMS)) are limited. Methods This ...

A study of more than 45,000 women found that screening women according to their level of risk was as effective in detecting tumors as the one-size-fits-most screening currently recommended. By Roni ...

Men account for higher rates of nearly all major chronic diseases — yet nearly two-thirds admit that they avoid going to the doctor for as long as possible, according to a Cleveland Clinic survey.

Tom Boggioni is a writer, born, raised and living in San Diego — where he attended San Diego State University. Prior to writing for Raw Story, he wrote for FireDogLake, blogged as TBogg, and worked in ...

MS NOW was the only major cable news network to post week-to-week gains in both total viewers and the key 25-54 demo during its first week after rebranding. The network averaged 1.014 million ...

MEMPHIS, Tenn. — Sheldon Timothy Herrington, the man who pleaded guilty to murdering University of Mississippi student Jimmie “Jay” Lee, received a 40-year sentence while in court on Tuesday morning.

People with multiple sclerosis (MS) who have higher levels of Fusobacterium nucleatum in the mouth — bacteria that can contribute to periodontitis, a serious gum infection — may be more likely to ...

The pro-Israel Stop Antisemitism group has named popular children’s YouTuber Ms Rachel among its ten "candidates" for the annual 'Antisemite of the Year' competition, in a list including individuals ...

MS NOW hosts Jonathan Capehart and Euegene Daniels were visibly shocked hearing about FBI Director Kash Patel's travel schedule and an apparent nickname some colleagues utter behind his back.

Living with multiple sclerosis (MS) often means dealing with different kinds of pain — some caused by damage to nerves, some by muscle stiffness or spasms, and some related to changes in how the body ...

Contineum Therapeutics (CTNM) shares fell following the results from its mid-stage trial of PIPE-307, a treatment aimed at patients with relapsing-remitting multiple sclerosis. The trial did not ...

The clock is up on Biogen’s extra two years of a biosimilar-free U.S. market for its blockbuster multiple sclerosis (MS) med Tysabri. After waiting in the wings post-FDA approval in 2023, Sandoz’s ...